Home / Data / Women's Health Trial Tracker Women's Health Trial Tracker Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.
Records 5,000
Last changed 10/10/2026
Update schedule 55 1 * * * UTC
Coverage 05/26/2000–10/09/2026 Record Record Date Vuga Group Change Status Recency Days Research Attention Score Women at Risk of Breast Cancer and OLFM4 01/12/2016 INTERVENTIONAL not-comparable 3,924.75 0 Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) 01/12/2016 OBSERVATIONAL not-comparable 3,924.75 0 The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer 01/12/2016 INTERVENTIONAL not-comparable 3,924.75 0 A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy 01/13/2016 INTERVENTIONAL not-comparable 3,923.75 0 Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility 01/15/2016 INTERVENTIONAL not-comparable 3,921.75 0 Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation 01/20/2016 INTERVENTIONAL not-comparable 3,916.75 0 Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer 01/20/2016 INTERVENTIONAL not-comparable 3,916.75 0 Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design 02/09/2016 INTERVENTIONAL not-comparable 3,896.75 0 Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA 02/18/2016 INTERVENTIONAL not-comparable 3,887.75 0 Vitamin D Dynamics in Women 03/10/2016 OBSERVATIONAL not-comparable 3,866.75 0 Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Severe Left Diaphragmatic Hernia (CDH) 03/17/2016 INTERVENTIONAL not-comparable 3,859.75 0 Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer 03/18/2016 INTERVENTIONAL not-comparable 3,858.75 0 A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction 03/31/2016 INTERVENTIONAL not-comparable 3,845.75 0 Feasibility and Tolerability of Transcranial Direct Current Stimulation With Concurrent Cognitive Training 04/04/2016 INTERVENTIONAL not-comparable 3,841.75 0 Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) 04/04/2016 INTERVENTIONAL not-comparable 3,841.75 0 MRI-Based Preoperative Accelerated Partial Breast Irradiation 04/05/2016 INTERVENTIONAL not-comparable 3,840.75 0 Standard Follow-up Program Cervix Cancer (SFP CERVIX) 04/11/2016 OBSERVATIONAL not-comparable 3,834.75 0 Zambian Preterm Birth Prevention Study 04/14/2016 OBSERVATIONAL not-comparable 3,831.75 0 Uterine Transplant in Absolute Uterine Infertility (AUIF) 04/18/2016 INTERVENTIONAL not-comparable 3,827.75 0 Lymphedema Surveillance Study 04/19/2016 OBSERVATIONAL not-comparable 3,826.75 0 DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer 04/20/2016 INTERVENTIONAL not-comparable 3,825.75 0 Biobank on Prematurity, Preeclampsia and Other Pregnancy Complications 04/20/2016 OBSERVATIONAL not-comparable 3,825.75 0 A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer 04/21/2016 INTERVENTIONAL not-comparable 3,824.75 0 Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer 04/25/2016 INTERVENTIONAL not-comparable 3,820.75 0 Breast Cancer WEight Loss Study (BWEL Study) 04/26/2016 INTERVENTIONAL not-comparable 3,819.75 0 Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer 04/27/2016 INTERVENTIONAL not-comparable 3,818.75 0 Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment 04/28/2016 INTERVENTIONAL not-comparable 3,817.75 0 A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer 04/28/2016 INTERVENTIONAL not-comparable 3,817.75 0 Trial to Compare Radiation Fibrosis With Five Versus Three Fractions 04/29/2016 INTERVENTIONAL not-comparable 3,816.75 0 Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations 05/04/2016 INTERVENTIONAL not-comparable 3,811.75 0 A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer 05/05/2016 INTERVENTIONAL not-comparable 3,810.75 0 Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) 05/06/2016 INTERVENTIONAL not-comparable 3,809.75 0 Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients 05/13/2016 OBSERVATIONAL not-comparable 3,802.75 0 Gastroschisis Outcomes of Delivery (GOOD) Study 05/17/2016 INTERVENTIONAL not-comparable 3,798.75 0 Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers 05/17/2016 INTERVENTIONAL not-comparable 3,798.75 0 Apremilast Pregnancy Exposure Registry 05/17/2016 OBSERVATIONAL not-comparable 3,798.75 0 Clinical Performance of B-Lite® Light Weight Breast Implant 05/19/2016 INTERVENTIONAL not-comparable 3,796.75 0 Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer 05/20/2016 INTERVENTIONAL not-comparable 3,795.75 0 Evaluating the Effects of Genetic Testing on Patients' Stress Levels 05/26/2016 OBSERVATIONAL not-comparable 3,789.75 0 Understanding and Predicting Breast Cancer Events After Treatment 06/07/2016 INTERVENTIONAL not-comparable 3,777.75 0 T-Cell Therapy for Advanced Breast Cancer 06/07/2016 INTERVENTIONAL not-comparable 3,777.75 0 Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions 06/16/2016 INTERVENTIONAL not-comparable 3,768.75 0 BMI-based Vitamins in Obese Pregnant Women 06/16/2016 INTERVENTIONAL not-comparable 3,768.75 0 KOrean Borderline Ovarian Tumor (KOBOT) Registry 06/17/2016 OBSERVATIONAL not-comparable 3,767.75 0 Vital-signs-integrated Patient-assisted Intravenous Opioid Analgesia 06/17/2016 INTERVENTIONAL not-comparable 3,767.75 0 Ovarian Cancer Hemoscope Trial 06/23/2016 OBSERVATIONAL not-comparable 3,761.75 0 Dried Plums and Bone Health in Postmenopausal Women 07/04/2016 INTERVENTIONAL not-comparable 3,750.75 0 Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer 07/11/2016 INTERVENTIONAL not-comparable 3,743.75 0 Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer 07/11/2016 INTERVENTIONAL not-comparable 3,743.75 0 Trial on Radical Upfront Surgery in Advanced Ovarian Cancer 07/11/2016 INTERVENTIONAL not-comparable 3,743.75 0
Source U.S. National Library of Medicine, ClinicalTrials.gov API v2 · official record · retrieved 10/10/2026 · upstream last modified 10/10/2026
Licence United States government work; public domain unless the source record says otherwise. Source: U.S. National Library of Medicine
Required notice Study records are informational and do not provide diagnosis, treatment advice, or an assessment of individual risk. What we add We compute Vuga Group, Change Status, Recency Days, Research Attention Score using the documented compute method. · methodology